comparemela.com

Latest Breaking News On - Hospital neuroepigenetics lab - Page 1 : comparemela.com

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

Massachusetts
United-states
Cambridge
Cambridgeshire
United-kingdom
Ghazaleh-sadri-vakili
Linkedin
Hospital-neuroepigenetics-lab
Neurosense-therapeutics-ltd
Prnewswire-neurosense-therapeutics-ltd
Twitter
Nasdaq

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

Massachusetts
United-states
Cambridge
Cambridgeshire
United-kingdom
Prnewswire-neurosense-therapeutics-ltd
Nasdaq
Neurosense-therapeutics-ltd
Linkedin
Hospital-neuroepigenetics-lab
Twitter

IceCure Medical, BrainStorm Cell Therapeutics and NeuroSense Therapeutics All Move Forward with Medtech

IceCure Medical, BrainStorm Cell Therapeutics, and NeuroSense Therapeutics are three Israeli medtech firms that all made new moves this week. BrainStorm Cell Therapeutics Inc., a developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting (‘ADCOM’) to discuss the company’s Biologics […]

Massachusetts
United-states
Israel
China
Chinese
Israeli
Shiran-zimri
Edmund-benami
Eyal-shamir
Micha-breakstone
Stacy-lindborg
Gil-shklarski

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.